Compounds as PDE IV and TNF-inhibitors

Details Compounds as PDE IV and TNF-inhibitors Compounds as PDE IV and TNF-inhibitors

2006-05-16

2006-05-16

Kumar, Shailendra (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

C564S086000, C564S158000, C564S162000, C564S163000, C564S165000, C564S170000, C564S171000, C564S172000, C564S180000, C564S442000, C568S631000, C560S029000, C560S039000, C558S415000, C546S309000, C544S238000, C544S334000, C544S345000, C548S146000, C548S206000, C514S247000, C514S256000, C514S290000, C514S352000, C514S357000, C514S365000, C514S372000, C514S522000, C514S534000, C514S478000, C514S617000, C514S618000, C514S619000, C514S718000

Reexamination Certificate

active

07045660

ABSTRACT:
This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF).Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.

REFERENCES:
patent: 4762922 (1988-08-01), Breuer
patent: 4808696 (1989-02-01), Matsuishi
patent: 5643914 (1997-07-01), Dalnes
patent: 5679696 (1997-10-01), Fenton et al.
patent: 5840724 (1998-11-01), Fenton et al.
patent: 5935977 (1999-08-01), Yamnazaki
patent: 5935978 (1999-08-01), Fenton et al.
patent: 5945425 (1999-08-01), Moormann
patent: 6096768 (2000-08-01), Ashton et al.
patent: 0 497 564 (1992-08-01), None
patent: 59176258 (1984-10-01), None
patent: 4360847 (1992-12-01), None
patent: WO 92/04888 (1982-04-01), None
patent: WO 89/05299 (1989-06-01), None
patent: WO 91/16303 (1991-10-01), None
patent: WO 92/12961 (1992-08-01), None
patent: WO 92/19594 (1992-11-01), None
patent: WO 93/07111 (1993-04-01), None
patent: WO 94/00437 (1994-01-01), None
patent: WO 94/02465 (1994-02-01), None
patent: 94/12461 (1994-06-01), None
patent: WO 95/20578 (1995-08-01), None
Barr et al., Palladium-Assisted Organic Reactions VIII, J. Organoment Chem., 302(1), 117-28 (1986).
Bagley et al., Synthesis of Nitidine (8,9-Dimethoxy-5-methyl-2,3-methylendioxy-benzo[c]phenanthridlnlum); a Comparison of Electrochemical and Photochemical Methods, J. Chem. Soc., Perkin Trans. 1 (20), 2924-6 (1977).
Ghosal et al., Chemical Constituens of Amaryllidaceae, Part 12, J. Chem. Res., Synop. (3), 100-1 (1985).
Kendurkar et al., Studies on Ylides, Formation and Reactoins of ortho- and meta-Nitrobenzylidenetriphenylarsenanes, J. Organomet Chem., 85(2), 173-8 (1975).
Kessar et al., Studies in Synthetic Photochemistry-1Synthesis of Naphthaphenanthridine Alkaloide, Tetrahedron Lell. (26), 2269-70 (1974).
Ninomiya et al., Synthesis of N-Demethylfagaronine, Heterocycles, 3(4), 307-9 (1975).
Smidrkal, Synthesis of Fagaronine, Collect.Czech.Chem.Comm., 53(12), 3184-92 (1988).
Villa et al., On the Leuckart Reaction of Deoxybenzoine, lsolation and Characterization of 2,3,4,5-Tetraarylpyridine Derivatives, Heterocycles, 24(7), 1943-54 (English) (1986).
Jang et al., Abstract, Korean J. Med. Chem., 2(2), 107-112, (1982).

Affiliated with

Also associated with

Rating

Compounds as PDE IV and TNF-inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds as PDE IV and TNF-inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds as PDE IV and TNF-inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3632599